Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pharmacyclics Inc PCYC

Healthcare Biotechnology

Recent & Breaking News (NDAQ:PCYC)

Pharmacyclics Receives 2014 Society for Medicines Research Award for Drug Discovery for Ibrutinib (IMBRUVICA®)

PR Newswire December 4, 2014

New IMBRUVICA® (ibrutinib) Application Accepted by European Medicines Agency for Waldenstrom's Macroglobulinemia

PR Newswire December 1, 2014

IMBRUVICA® (ibrutinib) Data to be Presented Across Multiple Histologies, Including in Eight Oral Presentations, at 2014 American Society of Hematology (ASH) Annual Meeting

PR Newswire November 6, 2014

Keith Lui Joins Versartis to Lead Global Marketing Efforts

GlobeNewswire November 6, 2014

Pharmacyclics Reports Third Quarter 2014 Financial Results and Provides Clinical Program Update

PR Newswire November 4, 2014

AstraZeneca And Pharmacyclics Enter Clinical Trial Collaboration To Evaluate IMBRUVICA® In Hematologic Cancers

PR Newswire November 4, 2014

AstraZeneca And Pharmacyclics Enter Immuno-Oncology Clinical Trial Collaboration With IMBRUVICA® In Solid Tumors

PR Newswire November 4, 2014

AstraZeneca, Pharmacyclics And Janssen Partner On Immuno-Oncology Combination Trials With IMBRUVICA® For Hematologic Cancers

PR Newswire November 4, 2014

Pharmacyclics Announces Conference Call to Discuss Third Quarter Financial Results

PR Newswire October 28, 2014

Pharmacyclics Files Supplemental New Drug Application for IMBRUVICA® for Waldenstrom's Macroglobulinemia

PR Newswire October 20, 2014

IMBRUVICA® (ibrutinib) Now Approved in Europe for Treatment of Two Blood Cancers

PR Newswire October 17, 2014

Pharmacyclics Enters Into Agreement with Roche to Evaluate IMBRUVICA® and GAZYVA® in Lymphoma and Leukemia

PR Newswire October 16, 2014

Bristol-Myers Squibb, Pharmacyclics and Janssen Announce Clinical Collaboration to Evaluate OPDIVO® (nivolumab) and IMBRUVICA®(ibrutinib) in Non-Hodgkin Lymphoma

Business Wire October 13, 2014

Pharmacyclics and Servier Agree to Conclude Pan-HDAC Inhibitor Collaboration

PR Newswire September 25, 2014

Pharmacyclics Appoints Chief Commercial Officer

PR Newswire August 18, 2014

Pharmacyclics Reports Second Quarter 2014 Results

PR Newswire July 31, 2014

Pharmacyclics Announces Date of Conference call to discuss Financial Results for Second Quarter of 2014

PR Newswire July 28, 2014

U.S. FDA Grants Regular (Full) Approval for IMBRUVICA® for Two Indications

PR Newswire July 28, 2014

European Medicines Agency (EMA) Issues Positive Opinion, Recommends Full Approval of IMBRUVICA® (ibrutinib) for Treatment of Two Blood Cancers

PR Newswire July 25, 2014

Immuno-Oncology Game-Changers from Big Pharma and Small Biotechs

Equities.com June 30, 2014